JRF103

JRF103 is a novel, orally administered pan-HER inhibitor that demonstrates potent in vitro activity against HER1 (also known as EGFR), HER2, and HER4. It is designed to target multiple members of the human epidermal growth factor receptor (HER/ErbB) family, including EGFR, which are implicated in the development and progression of various solid tumors. The drug is being developed primarily for the treatment of advanced solid tumors, particularly those with mutations such as EGFR/HER2 exon 20 insertions where no targeted therapies have previously been approved. Clinical studies are ongoing to evaluate its safety, pharmacokinetics, and anti-tumor efficacy in patients with advanced malignancies[1][2][3][4][6].